Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.
Fundz sees it the moment Verastem Oncology raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
NeedhamBiotechnologyHealthcareHealth CareTherapeuticsBiopharma